TrialCompass TCL
Back to results
Phase 2RecruitingPriority 3 · Moderate priorityNCT05182957

Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma

ClinicalTrials.gov

Plain-language summary

This Phase 2 trial is evaluating Anti-PD-1 monoclonal antibody, Lenalidomide, and other medications as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years or older
  • Newly diagnosed, not yet treated
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Anti-PD-1 monoclonal antibody (DRUG): Anti-PD-1 monoclonal antibody, 200mg i.v d1 (/21d) | Lenalidomide (DRUG): Lenalidomide 25mg qd po d1-d10 (/21d) | Azacitidine (DRUG): Azacitidine 75mg/m2 i.v d1-d7 (/21d)

Drugs / treatments
Anti-PD-1 monoclonal antibody, Lenalidomide, Azacitidine
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma

NCT05182957

Phase: Phase 2 | Status: Recruiting | Priority: Medium

Plain-language summary

This Phase 2 trial is evaluating Anti-PD-1 monoclonal antibody, Lenalidomide, and other medications as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join

  • Age 18 Years or older
  • Newly diagnosed, not yet treated
  • Must be well enough for treatment (adequate performance status)

What's being tested

Anti-PD-1 monoclonal antibody (DRUG): Anti-PD-1 monoclonal antibody, 200mg i.v d1 (/21d) | Lenalidomide (DRUG): Lenalidomide 25mg qd po d1-d10 (/21d) | Azacitidine (DRUG): Azacitidine 75mg/m2 i.v d1-d7 (/21d)

Drugs / treatments: Anti-PD-1 monoclonal antibody, Lenalidomide, Azacitidine

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 31 patients

Primary endpoint: Overall Response Rate (ORR) at 6 cycles

Ages: 18 Years to —

Start date: 2020-01-01 | Est. completion: 2026-06-15

Locations

0 US sites · 1 total

Contact

Caixia Li, M.D | licaixia@suda.edu.cn | +86 512 67781856

Sponsor: The First Affiliated Hospital of Soochow University (OTHER)

Tags

All T-cell lymphomas · Newly diagnosed · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT05182957

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.